John F. Crowley is our Chairman and CEO. John’s involvement with biotechnology stems from the 1998 diagnosis of two of his children with Pompe disease—a severe and often fatal neuromuscular disorder. In his drive to find a cure for them, he left his position at Bristol-Myers Squibb and became an entrepreneur as the Co-founder, President and CEO of Novazyme Pharmaceuticals, a biotech start-up conducting research on a new experimental treatment for Pompe disease (which he credits as ultimately saving his children’s lives). In 2001, Novazyme was acquired by Genzyme Corporation and John continued to play a lead role in the development of a drug for Pompe disease as Senior Vice President, Genzyme Therapeutics.
John and his family have been profiled on the front page of The Wall Street Journal and are the subjects of a book by Pulitzer prize-winning journalist Geeta Anand, “The Cure: How a Father Raised $100 Million-And Bucked the Medical Establishment-In a Quest to Save His Children.” The major motion picture, Extraordinary Measures, starring Brendan Fraser and Harrison Ford, is inspired by the Crowley family journey. John is the author of a personal memoir: Chasing Miracles: The Crowley Family Journey of Strength, Hope, and Joy.
John served as a commissioned officer in the U.S. Navy Reserve, assigned to the United States Special Operations Command, and is a veteran of the global war on terrorism, with service in Afghanistan. He graduated with a B.S. in Foreign Service from Georgetown University, and earned a J.D. from the University of Notre Dame Law School and an M.B.A. from Harvard. The Crowley family was the recipient of the 2011 Family Exemplar Award from the University of Notre Dame. He is also a member of the University Council on Science & Technology at Notre Dame and the Wall Street Journal CEO Council. Currently, John serves as a member of the Board of Directors of Intellia Therapeutics, Inc. and Entrada Therapeutics, Inc. He is the former National Chairman of the Make-A-Wish Foundation of America and is a founding Board member of the Global Genes Project. John is a Henry Crown Fellow at the Aspen Institute.
What is John F. Crowley's net worth?
The estimated net worth of John F. Crowley is at least $8.48 million as of February 15th, 2024. Mr. Crowley owns 697,628 shares of Entrada Therapeutics stock worth more than $8,476,180 as of April 20th. This net worth approximation does not reflect any other investments that Mr. Crowley may own. Learn More about John F. Crowley's net worth.
How do I contact John F. Crowley?
Has John F. Crowley been buying or selling shares of Entrada Therapeutics?
John F. Crowley has not been actively trading shares of Entrada Therapeutics in the last ninety days. Most recently, on Wednesday, January 12th, John F. Crowley bought 5,000 shares of Entrada Therapeutics stock. The stock was acquired at an average cost of $9.71 per share, with a total value of $48,550.00. Learn More on John F. Crowley's trading history.
Are insiders buying or selling shares of Entrada Therapeutics?
In the last twelve months, Entrada Therapeutics insiders bought shares 5 times. They purchased a total of 8,896 shares worth more than $119,271.76. In the last twelve months, insiders at the sold shares 21 times. They sold a total of 82,952 shares worth more than $1,280,746.80. The most recent insider tranaction occured on April, 8th when Director Peter S Kim bought 2,600 shares worth more than $35,282.00. Insiders at Entrada Therapeutics own 7.6% of the company.
Learn More about insider trades at Entrada Therapeutics. Information on this page was last updated on 4/8/2024.
